AngioSoma (OTC: SOAN) recently announced their intent to work with Biomedix to use PADnet for clinical research and trials, to evaluate the efficacy of their pharmaceutical intervention for PAD. AngioSoma intends to use the PADnet Read more…
John Martin, MD
"A unique feature of PADnet is its ability to break down barriers between specialists and primary physicians. Biomedix will train your staff. That makes a huge difference. They provide that comfort level with testing, and once they get that, they are off and running."